T. Kinoshita

发表

Identification of an allosteric and Smad3-selective inhibitor of p38αMAPK using a substrate-based approach.

Haruna Nagao, Daisuke Kitagawa, F. Nakajima, 2021, Bioorganic & medicinal chemistry letters.

Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening.

K. Kitaura, G. Tsujimoto, T. Kinoshita, 2015, European journal of medicinal chemistry.

Structural basis for producing selective MAP2K7 inhibitors.

N. London, T. Kinoshita, H. Barr, 2020, Bioorganic & medicinal chemistry letters.

5Z-7-Oxozeaenol covalently binds to MAP2K7 at Cys218 in an unprecedented manner.

M. Sawa, T. Kinoshita, T. Hashimoto, 2015, Bioorganic & medicinal chemistry letters.

Visualization of Molecular Length of α, ω-Diamines and Temperature by a Receptor Based on Phenolphthalein and Crown Ether (SYNTHETIC ORGANIC CHEMISTRY-Fine Organic Synthesis)

T. Kinoshita, K. Fuji, Kiyoshi Tanaka, 1999 .

Structural basis of compound recognition by adenosine deaminase.

T. Kinoshita, T. Fujii, Tsuyoshi Inoue, 2005, Biochemistry.

Structural basis for the inhibitor recognition of human Lyn kinase domain.

T. Kinoshita, K. Yokota, Y. Kirii, 2009, Bioorganic & medicinal chemistry letters.

FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase III. Structure determination.

T. Kinoshita, M. Hino, S. Yoshimura, 2003, The Journal of antibiotics.

A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase

K. Kitaura, G. Tsujimoto, H. Fukada, 2011, Molecular and Cellular Biochemistry.

Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor.

S. Albeck, T. Unger, N. London, 2019, Cell chemical biology.

Knowledge‐Based Identification of the ERK2/STAT3 Signal Pathway as a Therapeutic Target for Type 2 Diabetes and Drug Discovery

Shuhei Kinoshita, T. Kinoshita, K. Doi, 2011, Chemical biology & drug design.

Structural insights for producing CK2α1-specific inhibitors.

T. Kinoshita, A. Hirasawa, I. Nakanishi, 2019, Bioorganic & medicinal chemistry letters.

Crystal structures of human CK2α2 in new crystal forms arising from a subtle difference in salt concentration.

T. Kinoshita, T. Nakaniwa, M. Tsuyuguchi, 2018, Acta crystallographica. Section F, Structural biology communications.

Structure of bovine adenosine deaminase complexed with 6-hydroxy-1,6-dihydropurine riboside.

T. Kinoshita, T. Fujii, I. Nakanishi, 2003, Acta crystallographica. Section D, Biological crystallography.

Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP‐ribose) polymerase‐1/2 inhibitors

A. Iwashita, T. Kinoshita, N. Matsuoka, 2005, FEBS letters.

Hepatocyte Growth Factor-20140423

T. Kinoshita, Kunio Matsumoto, Katsuya Sakai, 2015 .

SmI2-Mediated Reduction of γ,γ-Difluoro-α,β-enoates with Application to the Synthesis of Functionalized (Z)-Fluoroalkene-Type Dipeptide Isosteres

T. Kinoshita, A. Otaka, H. Tamamura, 2004 .

Conformational change of adenosine deaminase during ligand-exchange in a crystal.

T. Kinoshita, I. Nakanishi, T. Tada, 2008, Biochemical and biophysical research communications.

Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors.

T. Kinoshita, Tadashi Terasaka, Katsuya Nakamura, 2003, Bioorganic & medicinal chemistry letters.

Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938.

T. Kinoshita, T. Fujii, Tadashi Terasaka, 2006, European journal of pharmacology.

High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7.

H. Fukada, M. Sawa, T. Kinoshita, 2017, Biochemical and biophysical research communications.

Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase.

T. Kinoshita, K. Yokota, H. Ishiguro, 2008, Protein expression and purification.

Crystallization and preliminary X-ray analysis of cephalosporin C acylase from Pseudomonas sp. strain N176.

T. Kinoshita, T. Tada, Y. Saito, 2000, Acta crystallographica. Section D, Biological crystallography.

A new antimitotic substance, FR182877. III. Structure determination.

T. Kinoshita, H. Terano, S. Yoshimura, 2000, The Journal of antibiotics.

Bivalent binding mode of an amino-pyrazole inhibitor indicates the potentials for CK2α1-selective inhibitors.

Daisuke Kitagawa, M. Sawa, T. Kinoshita, 2022, Biochemical and biophysical research communications.

Asymmetric synthesis of FR165914: A novel β3-adrenergic agonist with a benzocycloheptene structure

T. Kinoshita, I. Nakanishi, K. Hattori, 1995 .

Structure of human protein kinase CK2 alpha 2 with a potent indazole-derivative inhibitor.

K. Kitaura, G. Tsujimoto, T. Kinoshita, 2009, Acta crystallographica. Section F, Structural biology and crystallization communications.

Expression, purification, crystallization and preliminary X-ray diffraction studies of human liver regucalcin.

T. Kinoshita, T. Fujii, H. Nakajima, 2004, Acta crystallographica. Section D, Biological crystallography.

Cloning, expression, purification, crystallization and preliminary X-ray analysis of human liver glyceraldehyde-3-phosphate dehydrogenase.

T. Kinoshita, T. Fujii, H. Nakajima, 2004, Acta crystallographica. Section D, Biological crystallography.

Cloning, expression, purification, crystallization and preliminary diffraction analysis of the C-terminal catalytic domain of human poly(ADP-ribose) polymerase.

T. Kinoshita, T. Fujii, Masaichi Warizaya, 2004, Acta crystallographica. Section D, Biological crystallography.

Crystallization and preliminary X-ray diffraction studies of catalase-peroxidase from Synechococcus PCC 7942.

M. Tamoi, S. Shigeoka, T. Kinoshita, 2002, Acta crystallographica. Section D, Biological crystallography.

Improving quality and harvest period of protein crystals for structure-based drug design: effects of a gel and a magnetic field on bovine adenosine deaminase crystals.

T. Kinoshita, T. Fujii, M. Ataka, 2003, Acta crystallographica. Section D, Biological crystallography.

Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.

T. Kinoshita, Tadashi Terasaka, Takeshi Inoue, 2004, Journal of medicinal chemistry.

Enantiomeric recognition of amino acids using a chiral spiropyran derivative.

T. Kinoshita, H. Morikawa, K. Fuji, 2002, Chirality.

Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.

T. Kinoshita, N. Fujii, H. Ohno, 2016, Bioorganic & medicinal chemistry.

Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.

A. Iwashita, T. Kinoshita, N. Matsuoka, 2006, Bioorganic & medicinal chemistry.

Studies on cerebral protective agents. X. Synthesis and evaluation of anticonvulsant activities for novel 4,5,6,7-tetrahydrothieno[3,3-c]pyridines and related compounds.

T. Kinoshita, A. Kuno, M. Ohkubo, 1996, Chemical & pharmaceutical bulletin.

A novel synthesis of the pyrazolo[1,5-a]quinoline ring system. New N1-C2 bridged DNA gyrase inhibitors via a novel tandem 1,4-conjugate addition-Michael [3+2] annulation process

T. Kinoshita, H. Sasaki, D. Barrett, 1996 .

Synthesis of new 1,8-bridged tricyclic quinolones by a novel intramolecular arylation of N-1 tethered malonamides

T. Kinoshita, D. Barrett, M. Murata, 1995 .

Use of meso-ternaphthalene derivatives: linear recognition of the α,ω-diamines by homoditopic receptors

T. Kinoshita, K. Fuji, Kiyoshi Tanaka, 2002 .

Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative.

T. Kinoshita, T. Fujii, M. Neya, 2005, Bioorganic & medicinal chemistry letters.

Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.

Kazuo Kitaura, Shinya Oishi, Gozoh Tsujimoto, 2012, Journal of medicinal chemistry.

Studies on cerebral protective agents. IX. Synthesis of novel 1,2,3,4-tetrahydroisoquinolines as N-methyl-D-aspartate antagonists.

T. Kinoshita, I. Nakanishi, A. Kuno, 1996, Chemical & pharmaceutical bulletin.

Memory of chirality in diastereoselective alpha-alkylation of isoleucine and allo-isoleucine derivatives.

T. Kinoshita, T. Kawabata, K. Fuji, 2000, Organic letters.

Alkylation of 1-(N-(Hydroxymethyl)-N-methylamino)-4-quinolones. An Improved Preparation of Intermediates for Novel Potent Tricyclic Quinolone Antibacterial Agents.

T. Kinoshita, H. Sasaki, D. Barrett, 1996 .

A novel [3 + 2] annulation: synthesis and X-ray crystallographic structure of a novel tetrahydropyrazolo[1,5-a] quinoline, an intermediate towards new tricyclic quinolone antibacterials

T. Kinoshita, H. Sasaki, D. Barrett, 1996 .

Regio- and Stereoselective Synthesis of (E)-Alkene trans-Xaa-Pro Dipeptide Mimetics Utilizing Organocopper-Mediated Anti-SN2‘ Reactions

T. Kinoshita, A. Otaka, H. Tamamura, 2002 .

Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.

Takayoshi Kinoshita, Kenji Murano, Yoshiyuki Kido, 2004, Journal of medicinal chemistry.

True interaction mode of porcine pancreatic elastase with FR136706, a potent peptidyl inhibitor.

T. Kinoshita, I. Nakanishi, T. Tada, 2003, Bioorganic & medicinal chemistry letters.

Structure of porcine pancreatic elastase complexed with FR901277, a novel macrocyclic inhibitor of elastases, at 1.6 Å resolution

T. Kinoshita, I. Nakanishi, T. Tada, 2000, Biopolymers.

Palladium-Catalyzed asymmetric reduction of allylic esters with a new chiral monodentate ligand, 8-diphenylphosphino-8′-methoxy-1,1′-binaphthyl

M. Sakurai, T. Kinoshita, T. Kawabata, 1998 .

Unexpectedly facile racemization of 8-diphenylphosphinoyl-8′-methoxy-1,1′-binaphthyl

M. Sakurai, T. Kinoshita, T. Kawabata, 1996 .

Stepwise Construction of Some Hexahomooxacalix[3]arenes and Their Conformations in Solid State

T. Kinoshita, K. Fuji, Kiyoshi Tanaka, 1998 .

The First Example for Cycloenantiomeric Hexahomooxacalix[3]arenes

T. Kinoshita, K. Fuji, M. Kawada, 2001 .

Complexation of C60 with hexahomooxacalix[3]arenes and supramolecular structures of complexes in the solid state

T. Kinoshita, K. Fuji, Kiyoshi Tanaka, 1998 .

The First Example for Cycloenantiomeric Hexahomooxacalix[3]arenes.

T. Kinoshita, K. Fuji, M. Kawada, 2001 .

Synthesis of the proton-ionizable lariat crown ether and chiral recognition of primary amines

T. Kinoshita, K. Fuji, K. Tsubaki, 2002 .

Synthesis, structure, and ion-binding properties of new tetraoxacalix[3]arenes.

T. Kinoshita, K. Fuji, K. Tsubaki, 2001, The Journal of organic chemistry.

Complexation of C60 with Hexahomooxacalix[3]arenes and Supramolecular Structures of Complexes in the Solid State.

T. Kinoshita, K. Fuji, K. Tsubaki, 1998 .

The Supramolecular Structure of 1,4-Bis-(9-fluorenyl)-1,4-dihydro[60]fullerene with Hexahomotrioxacalix[3]arene in the Solid State

T. Kinoshita, Y. Murata, K. Fuji, 1999 .

The Novel Gluconeogenesis Inhibitor FR225654 that Originates from Phoma sp. No. 00144

T. Kinoshita, H. Nakajima, Y. Ohtsu, 2005, The Journal of Antibiotics.

Stereoselective synthesis of CF(2)-substituted phosphothreonine mimetics and their incorporation into peptides using newly developed deprotection procedures.

T. Kinoshita, A. Otaka, H. Tamamura, 2000, The Journal of organic chemistry.

FR177391, A New Anti-hyperlipidemic Agent from Serratia

T. Kinoshita, H. Nakajima, H. Terano, 2005, The Journal of Antibiotics.

Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth

T. Hirota, S. Kay, F. Tama, 2019, Science Advances.

Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.

K. Kitaura, G. Tsujimoto, T. Kinoshita, 2009, Bioorganic & medicinal chemistry letters.

Synthesis, X-ray crystal structure, and biological activity of FR186054, a novel, potent, orally active inhibitor of acyl-CoA:cholesterol O-acyltransferase (ACAT) bearing a pyrazole ring.

T. Kinoshita, H. Tanaka, A. Tanaka, 1998, Bioorganic & medicinal chemistry letters.

Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds.

T. Kinoshita, T. Matsuo, T. Tada, 1994, Chemical & pharmaceutical bulletin.

Hydration Structures of the Human Protein Kinase CK2α Clarified by Joint Neutron and X-ray Crystallography.

T. Kinoshita, R. Kuroki, Y. Kurosaki, 2018, Journal of molecular biology.

Structure of human Fyn kinase domain complexed with staurosporine.

T. Kinoshita, H. Ishiguro, M. Matsubara, 2006, Biochemical and biophysical research communications.

Molecular basis of histone H 3 K 4 ME 3 recognition by ING 4

G. Montoya, K. Niwa, D. Pantoja-Uceda, 2008 .

Crystallization and preliminary analysis of bovine adenosine deaminase.

T. Kinoshita, N. Nishio, A. Sato, 1999, Acta crystallographica. Section D, Biological crystallography.

Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex.

T. Kinoshita, S. Nishimura, M. Neya, 2005, Biochemical and biophysical research communications.

Crystal structure of human mono-phosphorylated ERK1 at Tyr204.

Koichi Yokota, Setsu Nakae, Toshiji Tada, 2008, Biochemical and biophysical research communications.

Identification of a novel target site for ATP-independent ERK2 inhibitors.

Haruna Nagao, M. Sawa, T. Kinoshita, 2022, Biochemical and biophysical research communications.

Synthesis of the water-soluble adenosine A1 receptor antagonist FR166124 through a novel sequential Horner-Emmons / isomerization reaction

T. Kinoshita, I. Nakanishi, K. Durkin, 1999 .

Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.

T. Kinoshita, Y. Tenda, K. Durkin, 1999, Bioorganic & medicinal chemistry letters.

Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)- pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity.

T. Kinoshita, K. Yoshida, T. Kusunoki, 1999, Journal of medicinal chemistry.

Protein Allostery in Rational Drug Design.

T. Kinoshita, 2019, Advances in experimental medicine and biology.

Assessment of the Activity of 8-Diphenylphosphino-8'-methoxy-1,1'-binaphthyl as a Ligand for Palladium-Catalyzed Reactions

M. Sakurai, T. Kinoshita, T. Kawabata, 1997 .

Assessment of the Activity of 8-Diphenylphosphino-8′-methoxy-1,1′-binaphthyl as a Ligand for Palladium-Catalyzed Reactions.

M. Sakurai, T. Kinoshita, T. Kawabata, 1998 .

Title Structure-Based Drug Design ConsideringInhibitor-Induced Conformational Change

T. Kinoshita, 2022 .

Recognition of the chain length of α,ω-diamines by a meso-ternaphthalene derivative with two crown ethers

T. Kinoshita, K. Fuji, K. Tsubaki, 2000 .

Crystallization and main-chain structure of neutral protease from Streptomyces caespitosus.

Y. Kai, N. Kasai, T. Kinoshita, 1991, Journal of biochemistry.

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model

T. Kinoshita, S. Yano, A. Tajima, 2018, Clinical Cancer Research.

Combined high-resolution neutron and X-ray analysis of inhibited elastase confirms the active-site oxyanion hole but rules against a low-barrier hydrogen bond.

T. Kinoshita, R. Kuroki, T. Ohhara, 2009, Journal of the American Chemical Society.

Structure of NADP-dependent glyceraldehyde-3-phosphate dehydrogenase from Synechococcus PCC7942 complexed with NADP.

M. Tamoi, S. Shigeoka, T. Kinoshita, 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.

Crystallization and preliminary X-ray diffraction analysis of NADP-dependent glyceraldehyde-3-phosphate dehydrogenase of Synechococcus PCC 7942.

M. Tamoi, S. Shigeoka, T. Kinoshita, 2001, Acta crystallographica. Section D, Biological crystallography.

Purification, crystallization and preliminary X-ray diffraction analysis of the fructose-1,6-/sedoheptulose-1,7-bisphosphatase of Synechococcus PCC 7942.

M. Tamoi, S. Shigeoka, T. Kinoshita, 2001, Acta crystallographica. Section D, Biological crystallography.

The Trial of Drug Discovery using the In-Silico Screening Methods Developed by Pharmaceutical Innovation Value Chain

Y. Fukunishi, Haruki Nakamura, Y. Okuno, 2010 .

Crystal structure of non-phosphorylated MAP2K6 in a putative auto-inhibition state.

Koichi Yokota, Toshiji Tada, Takayoshi Kinoshita, 2012, Journal of biochemistry.

Structure of the zinc endoprotease from Streptomyces caespitosus.

Y. Kai, N. Kasai, T. Kinoshita, 1997, Journal of biochemistry.

Complete amino acid sequence of a zinc metalloendoprotease from Streptomyces caespitosus.

N. Kasai, T. Kinoshita, S. Tsunasawa, 1995, European journal of biochemistry.

Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay.

T. Kinoshita, N. Takahashi, H. Sugiyama, 2016, Bioorganic & medicinal chemistry letters.

Seven cysteine-deficient mutants depict the interplay between thermal and chemical stabilities of individual cysteine residues in mitogen-activated protein kinase c-Jun N-terminal kinase 1.

H. Fukada, T. Kinoshita, R. Kuroki, 2012, Biochemistry.

Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.

Yasuko Kato, Takayoshi Kinoshita, T. Kinoshita, 2005, Journal of medicinal chemistry.

Inhibitor‐induced structural change of the active site of human poly(ADP‐ribose) polymerase

Takayoshi Kinoshita, Yoshiyuki Kido, A. Iwashita, 2004, FEBS letters.

Hepatocyte Growth Factor

T. Kinoshita, Kunio Matsumoto, Katsuya Sakai, 2014 .

Crystal and solution structures disclose a putative transient state of mitogen-activated protein kinase kinase 4.

T. Kinoshita, A. Yamano, Y. Kirii, 2012, Biochemical and biophysical research communications.

Crystal structures of MKK4 kinase domain reveal that substrate peptide binds to an allosteric site and induces an auto-inhibition state.

T. Kinoshita, K. Yokota, Y. Kirii, 2010, Biochemical and biophysical research communications.

Role of a cysteine residue in the active site of ERK and the MAPKK family.

Seiji Yoshimura, Hidenori Nakajima, Takayoshi Kinoshita, 2007, Biochemical and biophysical research communications.

Protein Crystallization by Combining Laser Irradiation and Solution-Stirring Techniques

Tsuyoshi Inoue, Yusuke Mori, Hiroaki Adachi, 2005 .

A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization.

Takayoshi Kinoshita, T. Kinoshita, Tadashi Terasaka, 2004, Journal of the American Chemical Society.

The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity.

T. Kinoshita, Tomonaga Ozawa, C. Handa, 2017, Bioorganic & medicinal chemistry letters.

Molecular structure of FR901277, a novel inhibitor of human leukocyte elastase, and its binding mode simulation.

T. Kinoshita, H. Hatanaka, I. Nakanishi, 1999, Bioorganic & medicinal chemistry letters.

An isoform-selective inhibitor of tropomyosin receptor kinase A behaves as molecular glue.

M. Sawa, T. Kinoshita, Tomonaga Ozawa, 2019, Bioorganic & medicinal chemistry letters.

Structural basis for the antiproliferative activity of the Tob-hCaf 1 complex

G. Montoya, K. Niwa, D. Pantoja-Uceda, 2008 .

Crystal structure of human CK2α at 1.06 Å resolution

T. Kinoshita, I. Nakanishi, Shinya Nakamura, 2013, Journal of synchrotron radiation.

Ensemble structural analyses depict the regulatory mechanism of non-phosphorylated human MAP2K4.

H. Fukada, M. Sawa, T. Kinoshita, 2019, Biochemical and biophysical research communications.

A crucial role of Cys218 in configuring an unprecedented auto-inhibition form of MAP2K7.

M. Sawa, T. Kinoshita, T. Hashimoto, 2016, Biochemical and biophysical research communications.

Bioconversion of FR901459, a novel derivative of cyclosporin A, by Lentzea sp. 7887

T. Kinoshita, S. Yoshimura, H. Ohki, 2015, The Journal of Antibiotics.

Crystal structure of CK2a1 with 5-iodotubercidin

M. Sawa, T. Kinoshita, I. Nakanishi, 2019 .

Design, Synthesis and Structure-Activity Relationship Studies of Protein Kinase CK2 Inhibitors Containing a Purine Scaffold.

T. Kinoshita, Shinya Nakamura, K. Nishiwaki, 2023, Chemical & pharmaceutical bulletin.

High-resolution structure of exo-arabinanase from Penicillium chrysogenum.

T. Kinoshita, K. Takano, Tsuyoshi Inoue, 2011, Acta crystallographica. Section D, Biological crystallography.

Structure of apo-glyceraldehyde-3-phosphate dehydrogenase from Synechococcus PCC7942.

M. Tamoi, S. Shigeoka, T. Kinoshita, 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.

Combined high-resolution neutron and X-ray analysis of inhibited elastase confirms the active-site oxyanion hole but rules against a low-barrier hydrogen bond.

T. Kinoshita, R. Kuroki, T. Ohhara, 2009, Journal of the American Chemical Society.

A promiscuous kinase inhibitor delineates the conspicuous structural features of protein kinase CK2a1.

M. Sawa, T. Kinoshita, I. Nakanishi, 2019, Acta crystallographica. Section F, Structural biology communications.

Crystallization of porcine pancreatic elastase and a preliminary neutron diffraction experiment.

T. Kinoshita, R. Kuroki, T. Ohhara, 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.